SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

\Box	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
	Instruction I(D).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number:	3235-0287										
Estimated average	hurden										

Estimated average burden hours per response:	
hours per response:	0.5

1. Name and Address of Reporting Person [*] Papkoff Jacqueline Sybil			2. Issuer Name and Ticker or Trading Symbol <u>ASSEMBLY BIOSCIENCES, INC.</u> [ASMB]		tionship of Reporting Person all applicable) Director Officer (give title	n(s) to Issuer 10% Owner Other (specify
	(First) 7 BIOSCIENCES, TREET, 4TH FLC		3. Date of Earliest Transaction (Month/Day/Year) 12/12/2018	Λ	below) See Remarks	below)
(Street) SAN CA 94158 FRANCISCO		94158	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing (C Form filed by One Reporti Form filed by More than O Person	ng Person
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount (A) or Brice			Transaction(s) (Instr. 3 and 4)	tion(s)	
Common Stock	12/12/2018		A		10,625(1)	Α	\$ <mark>0</mark>	10,625	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Expiration Date Derivative (Month/Day/Year) Securities			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$24.19	12/12/2018		A		21,250		(2)	12/12/2028	Common Stock	21,250	\$0	21,250	D	

Explanation of Responses:

 Represents shares of common stock issuable under a time-based restricted stock unit (RSU) award dated December 12, 2018 that was granted under Assembly Biosciences, Inc.'s 2018 Stock Incentive Plan (2018 Plan). The RSUs vest in approximately equal annual installments, assuming continuous service on each vesting date, on the first, second and third anniversaries of the date of grant.
 Grant of stock options under the 2018 Plan. The stock options vest in approximately equal annual installments, assuming continuous service on each vesting date, on the first, second and third anniversaries of

2. Grant of stock options under the 2018 Plan. The stock options vest in approximately equal annual installments, assuming continuous service on each vesting date, on the first, second and third anniversaries of the date of grant.

Remarks:

SVP-Chief Scientific Officer Microbiome

/s/ Elizabeth H. Lacy, as

Attorney-in-Fact

12/14/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.